Citations 1
AASLD IDSA Practice Guideline on treatment of chronic hepatitis B
Ghany, Marc G. , Frick, Andrew , Lok, Anna S. , Feld, Jordan J. , Lim, Joseph K. , Wang, Su H. , Kim, A Y, Tang, Amy S. , Nguyen, Mindie H. , Naggie, Susanna, Sulkowski, Mark S. , RodriguezâBaez, Norberto, Chen, Jacki, Mohammad, Khaled S. , Kim, Arthur Y. , Naggie, Susanna , Pan, Calvin Q , Kim, Arthur Y , Naggie, Susanna , Murad, M Hassan , Mohammad, Khaled S , Terrault, Norah , Nguyen, Mindie H , Chen, Jacki, Terrault, Norah A.
Hepatology | November 4, 2025 | Volume: 83 | Issue: 4 | Pages: 974-997
Background and Aims: Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Methods: The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline. Conclusions: This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.